SOURCE: Active Biotech

September 30, 2010 02:41 ET

Number of shares and votes in Active Biotech

LUND, SWEDEN--(Marketwire - September 30, 2010) -

The number of shares and votes in Active Biotech has changed as a result of the exercise of employee stock options.

Today, the last trading day of the month, there are in total 65,967,864 shares and votes in Active Biotech.


Lund, September 30, 2010
Active Biotech AB (publ)

For further information, please contact:
Hans Kolam, CFO
Tel: +46 (0)46 19 20 44
E-mail:hans.kolam@activebiotech.com

About Active Biotech

Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. Projects in or entering pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, TASQ for prostate cancer as well as ANYARA for use in cancer targeted therapy, primarily of renal cell cancer. In addition, laquinimod is in Phase II development for Crohn's and Lupus. Further projects in clinical development comprise the two orally administered compounds, 57-57 for SLE & Systemic Sclerosis and RhuDex™ for RA. Please visitwww.activebiotech.com for more information.

Active Biotech AB
PO Box 724, SE-220 07 Lund
Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00

Active Biotech is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submitted for publication at 08:30 a.m. CET on September 30, 2010.


[HUG#1445803]


Number of shares and votes in Active Biotech: http://hugin.info/1002/R/1445803/388952.pdf


This announcement is distributed by Thomson Reuters on behalf of

Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and

other applicable laws; and

(ii) they are solely responsible for the content, accuracy and

originality of the information contained therein.


Source: Active Biotech via Thomson Reuters ONE

Contact Information